Vaccinex Inc (VCNX)

Panoramica Notizia Cronologia dei prezzi Financials Perché VCNX Giù? Forum Previsione Frazionamento azionario

Precedente Chiudi:

Volume 24 ore:

Relative Volume:

Capitalizzazione di mercato:

Utile/perdita netta:

Rapporto P/E:

Flusso di cassa netto:

1 W Prestazione:

1M Prestazione:

6M Prestazione:

1 anno Prestazione:

Intervallo 1D:

Intervallo di 1 settimana:

Portata 52W:

Vaccinex Inc Stock (VCNX) Company Profile

Vaccinex Inc

Healthcare (1113)

Biotechnology (621)

Prossima data di guadagno

Ultimi documenti SEC

VCNX's Discussions on Twitter

Confronta VCNX con altri titoli

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
VCNX Vaccinex Inc	0.98	0	0	-22.01M	-18.31M	-85.40
VRTX Vertex Pharmaceuticals Inc	469.68	122.84B	11.74B	3.68B	3.34B	14.19
REGN Regeneron Pharmaceuticals Inc	801.01	85.37B	14.25B	4.58B	3.88B	41.77
ALNY Alnylam Pharmaceuticals Inc	399.40	55.82B	3.21B	43.57M	221.36M	0.2405
ARGX Argen X Se Adr	795.57	50.67B	3.06B	1.28B	447.35M	19.67
INSM Insmed Inc	170.27	37.54B	447.02M	-1.18B	-906.14M	-6.1812

Vaccinex Inc Stock (VCNX) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2020-09-23	Downgrade	BTIG Research	Buy → Neutral
2018-09-04	Iniziato	Ladenburg Thalmann	Buy

Vaccinex Inc Borsa (VCNX) Ultime notizie

Vaccinex Inc Azioni (VCNX) Dati Finanziari

Vaccinex Inc (VCNX)

Vaccinex Inc Stock (VCNX) Company Profile

Confronta VCNX con altri titoli

Vaccinex Inc Stock (VCNX) Upgrades & Downgrades

Vaccinex Inc Borsa (VCNX) Ultime notizie

Best Biotech Penny Stocks Right Now • Updated Daily - Benzinga

Head to Head Contrast: Evofem Biosciences (NASDAQ:EVFM) versus Vaccinex (NASDAQ:VCNX) - Defense World

Micro Cap Biotech Secures $60M to Advance Alzheimer’s Treatment, Shares Surge - The Globe and Mail

Vaccinex secures $60 million funding for Alzheimer’s drug development By Investing.com - Investing.com Australia

Vaccinex announces $60M revenue sharing agreement with PDV - MSN

Vaccinex Secures $60 Mln To Advance Enlarged Phase 2b Alzheimer's Trial - Nasdaq

Vaccinex secures $60 million funding for Alzheimer’s drug development - Investing.com

Vaccinex, Inc. Engages in $60 Million Revenue Sharing Agreement with Pepinemab Development Venture to Advance Alzheimer’s Treatment - Quiver Quantitative

Net Asset Value(s) - The Manila Times

Biometric Identification / Cybersecurity SaaS Solutions Provider BIO-key Presents at DealFlow Discovery Investor Conference Jan. 28 & 29 in Atlantic City, NJ - The Manila Times

Vaccinex, Inc. Announces $60 million Agreement to Finance a Phase 2b clinical trial of pepinemab to treat Alzheimer’s Disease - The Manila Times

MBAK Energy Solutions, Inc. (OTC:MBAK) partners with Carbon Zero Mobility in Kenya and the University of Michigan on Charger Design - The Manila Times

Outpace Wins 144+ SEO Awards, Establishing Itself as one of the Best SEO Agencies in the US - The Manila Times

Renewal Fuels (RNWF) & Its Subsidiary American Fusion Highlight Near-Term Commercial Fusion Strategy, Underscoring Key Distinctions Between Deployable Energy Infrastructure & Experimental Fusion Programs - The Manila Times

SunPower Q3’25 10Q Report Filed - The Manila Times

OSS Receives Follow-On Production Order from Safran Federal Systems - The Manila Times

Reviva Announces Regulatory Update Regarding the Development of Brilaroxazine for the Treatment of Schizophrenia - The Manila Times

Bone Biologics Improves Extension of rhNELL-1 Product Shelf Life to 24 Months - The Manila Times

ZenaTech Closes Acquisition of Vara 3D, a Utah-Based Surveying and Mapping Firm Expanding Drone-as-a-Service to the High-Growth Solar Infrastructure Market - The Manila Times

Getty Realty Corp. To Report Fourth Quarter 2025 Financial Results - The Manila Times

dLocal completes transition to a majority independent Board with appointments of Paco Ybarra and Nelson Mattos - The Manila Times

Cassava Announces Agreement to Settle Securities Class Action Litigation - The Manila Times

Quantum Biopharma Announces Completion of Dosing in 180-Day Repeated Dose Oral Toxicity and Toxicokinetic Studies for Lucid-21-302 (Lucid-MS) - The Manila Times

Profound Medical Corp. Closes $36 Million Registered Direct Offering; Expects to Complete Subsequent Private Placement On or Before December 30th - The Manila Times

Genius Group Acquires Lighthouse Studios, to Launch Genius Studios. - The Manila Times

Nuvini Announces Strategic Restructuring of Earnout Liabilities with 36% Reduction - The Manila Times

CooperCompanies Appoints Walter M Rosebrough, Jr. to its Board of Directors - The Manila Times

Join Jupiter Neurosciences’ Exclusive Live Investor Webinar and Q&A Session on January 6 - The Manila Times

Safe Harbor Expands Consulting and Managed Services Platform Through Talent-Led Strategic Transaction - The Manila Times

Ronald P. Mathison and MATCO Investments Ltd. File Early Warning Report Regarding Calfrac Well Services Ltd. - The Manila Times

Willis Lease Finance Corporation Announces Closing of $392,900,000 in Fixed Rate Notes - The Manila Times

Director/PDMR Shareholding - The Manila Times

Baiya International Group Inc. Announce Reverse Split Record Date - The Manila Times

Aspocomp Group Plc: Notification of management’s transactionTerhi Launis (acquisition) - The Manila Times

Vaccinex, Inc. Announces $60 million Agreement to Finance - GlobeNewswire

Vaccinex, Inc. Enters into a $60 Million Revenue Sharing Agreement with Pepinemab Development Venture, LP - MarketScreener

Analyzing Whitehawk Therapeutics (NASDAQ:WHWK) & Vaccinex (NASDAQ:VCNX) - Defense World

NeurAxis, Inc. (NRXS) Analyst insights, Price targets and Recommendations - Yahoo Finance UK

AIM ImmunoTech Inc. (AIMI) Analyst insights, Price targets and Recommendations - Yahoo Finance UK

Revenue per share of Vaccinex, Inc. – OTC:VCNX - TradingView

Vaccinex (NASDAQ:VCNX) Trading 4.2% Higher – Time to Buy? - Defense World

Vaccinex (NASDAQ:VCNX) Stock Price Down 5.7% – Time to Sell? - Defense World

Contrasting Vaccinex (NASDAQ:VCNX) & Palatin Technologies (PINK:PTNT) - Defense World

NF-κB Inhibitors Market to Witness Accelerated Expansion Across the 7MM through 2034 | DelveInsight - PR Newswire UK

What sets apart Novavax option from other COVID-19 vaccines - American Medical Association

Vaccinex, Inc. (NASDAQ:VCNX) Sees Significant Growth in Short Interest - Defense World

GLP-1 Agonists Market to Show Impressive Growth at a CAGR of 10.8% During the Forecast Period (2025-2034) | DelveInsight - PR Newswire

Senators from both parties grilled RFK Jr. on vaccines and more - NPR

Vaccine Development - Gates Foundation

TR | OpenAI4o Maintains Vaccinex(VCNX.US) With Hold Rating, Cuts Target Price to $0.5 - 富途牛牛

Head to Head Survey: Aerovate Therapeutics (NASDAQ:AVTE) vs. Vaccinex (NASDAQ:VCNX) - Defense World

Vaccinex Inc Azioni (VCNX) Dati Finanziari

Reddito

Reddito netto

Flusso di cassa

EPS

Simile a VCNX